Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 1
2005 5
2006 4
2007 10
2008 13
2009 11
2010 20
2011 29
2012 23
2013 10
2014 13
2015 17
2016 11
2017 8
2018 9
2019 9
2020 8
2021 8
2022 5
2023 6
2024 9
2025 2

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

208 results

Results by year

Filters applied: . Clear all
Page 1
Block of A1 astrocyte conversion by microglia is neuroprotective in models of Parkinson's disease.
Yun SP, Kam TI, Panicker N, Kim S, Oh Y, Park JS, Kwon SH, Park YJ, Karuppagounder SS, Park H, Kim S, Oh N, Kim NA, Lee S, Brahmachari S, Mao X, Lee JH, Kumar M, An D, Kang SU, Lee Y, Lee KC, Na DH, Kim D, Lee SH, Roschke VV, Liddelow SA, Mari Z, Barres BA, Dawson VL, Lee S, Dawson TM, Ko HS. Yun SP, et al. Among authors: lee s. Nat Med. 2018 Jul;24(7):931-938. doi: 10.1038/s41591-018-0051-5. Epub 2018 Jun 11. Nat Med. 2018. PMID: 29892066 Free PMC article.
Editorial.
Soo Suk J, Suh J, Cui H, Kim AJ, Lee S, Yeo Y. Soo Suk J, et al. Among authors: lee s. J Control Release. 2017 Dec 10;267:1. doi: 10.1016/j.jconrel.2017.11.014. J Control Release. 2017. PMID: 29221503 No abstract available.
Safety, tolerability, and efficacy of NLY01 in early untreated Parkinson's disease: a randomised, double-blind, placebo-controlled trial.
McGarry A, Rosanbalm S, Leinonen M, Olanow CW, To D, Bell A, Lee D, Chang J, Dubow J, Dhall R, Burdick D, Parashos S, Feuerstein J, Quinn J, Pahwa R, Afshari M, Ramirez-Zamora A, Chou K, Tarakad A, Luca C, Klos K, Bordelon Y, St Hiliare MH, Shprecher D, Lee S, Dawson TM, Roschke V, Kieburtz K. McGarry A, et al. Among authors: lee s. Lancet Neurol. 2024 Jan;23(1):37-45. doi: 10.1016/S1474-4422(23)00378-2. Lancet Neurol. 2024. PMID: 38101901 Clinical Trial.
TRAIL agonists rescue mice from radiation-induced lung, skin, or esophageal injury.
Strandberg J, Louie A, Lee S, Hahn M, Srinivasan P, George A, De La Cruz A, Zhang L, Hernandez Borrero L, Huntington KE, De La Cruz P, Seyhan AA, Koffer PP, Wazer DE, DiPetrillo TA, Graff SL, Azzoli CG, Rounds SI, Klein-Szanto AJ, Tavora F, Yakirevich E, Abbas AE, Zhou L, El-Deiry WS. Strandberg J, et al. Among authors: lee s. J Clin Invest. 2025 Jan 14;135(5):e173649. doi: 10.1172/JCI173649. J Clin Invest. 2025. PMID: 39808500 Free PMC article.
The Effects of NLY01, a Novel Glucagon-Like Peptide-1 Receptor Agonist, on Cuprizone-Induced Demyelination and Remyelination: Challenges and Future Perspectives.
Gharagozloo M, Galleguillos D, Jank L, Sotirchos ES, Smith MD, Garton T, Kumar S, Hussein O, Potluri S, Taylor M, Siu C, Mace JW, Dawson T, Dawson VL, Lee S, Calabresi PA. Gharagozloo M, et al. Among authors: lee s. Neurotherapeutics. 2023 Jul;20(4):1229-1240. doi: 10.1007/s13311-023-01390-4. Epub 2023 Jun 9. Neurotherapeutics. 2023. PMID: 37296356 Free PMC article.
Nanoparticle-based theranostic agents.
Xie J, Lee S, Chen X. Xie J, et al. Among authors: lee s. Adv Drug Deliv Rev. 2010 Aug 30;62(11):1064-79. doi: 10.1016/j.addr.2010.07.009. Epub 2010 Aug 4. Adv Drug Deliv Rev. 2010. PMID: 20691229 Free PMC article. Review.
Protease-activated drug development.
Choi KY, Swierczewska M, Lee S, Chen X. Choi KY, et al. Among authors: lee s. Theranostics. 2012;2(2):156-78. doi: 10.7150/thno.4068. Epub 2012 Feb 8. Theranostics. 2012. PMID: 22400063 Free PMC article.
208 results